BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Forlano R, Mullish BH, Mukherjee SK, Nathwani R, Harlow C, Crook P, Judge R, Soubieres A, Middleton P, Daunt A, Perez-Guzman P, Selvapatt N, Lemoine M, Dhar A, Thursz MR, Nayagam S, Manousou P. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS One. 2020;15:e0240400. [PMID: 33031439 DOI: 10.1371/journal.pone.0240400] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Anirvan P, Singh SP, Giammarino A, Satapathy SK. Association of non-alcoholic fatty liver disease and COVID-19: A literature review of current evidence. World J Hepatol 2021; 13(8): 916-925 [PMID: 34552698 DOI: 10.4254/wjh.v13.i8.916] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Madan K, Rastogi R, Bhargava R, Dagar V, Singla V, Sahu A, Singh P, Garg P, Aggarwal B, Singh RK. Is Fatty Liver associated with increased mortality and morbidity in patients with COVID-19 pneumonia? Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.04.013] [Reference Citation Analysis]
3 Bellanti F, Vendemiale G. Coronavirus disease 2019 and non-alcoholic fatty liver disease. World J Hepatol 2021; 13(9): 969-978 [PMID: 34630869 DOI: 10.4254/wjh.v13.i9.969] [Reference Citation Analysis]
4 Tao Z, Li Y, Cheng B, Zhou T, Gao Y. Risk of Severe COVID-19 Increased by Metabolic Dysfunction-associated Fatty Liver Disease: A Meta-analysis. J Clin Gastroenterol 2021;55:830-5. [PMID: 34406175 DOI: 10.1097/MCG.0000000000001605] [Reference Citation Analysis]
5 Jeyakumar SM, Vajreswari A. Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids. World J Clin Cases 2021; 9(31): 9333-9349 [PMID: 34877270 DOI: 10.12998/wjcc.v9.i31.9333] [Reference Citation Analysis]
6 Ilias I, Goulas S, Zabuliene L. Polycystic ovary syndrome: Pathways and mechanisms for possible increased susceptibility to COVID-19. World J Clin Cases 2021; 9(12): 2711-2720 [PMID: 33969054 DOI: 10.12998/wjcc.v9.i12.2711] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Miele L, Napodano C, Cesario A, De Magistris A, Pocino K, Basile U, Rapaccini GL, Gasbarrini A, Grieco A. COVID-19, adaptative immune response and metabolic-associated liver disease. Liver Int 2021;41:2560-77. [PMID: 34555255 DOI: 10.1111/liv.15061] [Reference Citation Analysis]
8 Vasques-Monteiro IML, Souza-Mello V. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight. World J Gastroenterol 2021; 27(16): 1738-1750 [PMID: 33967554 DOI: 10.3748/wjg.v27.i16.1738] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Calapod OP, Marin AM, Onisai M, Tribus LC, Pop CS, Fierbinteanu-Braticevici C. The Impact of Increased Fib-4 Score in Patients with Type II Diabetes Mellitus on Covid-19 Disease Prognosis. Medicina (Kaunas) 2021;57:434. [PMID: 33946377 DOI: 10.3390/medicina57050434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yoo HW, Jin HY, Yon DK, Effenberger M, Shin YH, Kim SY, Yang JM, Kim MS, Koyanagi A, Jacob L, Smith L, Yoo IK, Shin JI, Lee SW. Non-alcoholic Fatty Liver Disease and COVID-19 Susceptibility and Outcomes: a Korean Nationwide Cohort. J Korean Med Sci 2021;36:e291. [PMID: 34697932 DOI: 10.3346/jkms.2021.36.e291] [Reference Citation Analysis]
11 Younossi ZM, Stepanova M, Lam B, Cable R, Felix S, Jeffers T, Younossi E, Pham H, Srishord M, Austin P, Estep M, Terra K, Escheik C, de Avila L, Golabi P, Kolacevski A, Racila A, Henry L, Gerber L. Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID-19 Infection. Hepatol Commun 2021. [PMID: 34558853 DOI: 10.1002/hep4.1802] [Reference Citation Analysis]
12 Singh A, Hussain S, Antony B. Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis. Diabetes Metab Syndr 2021;15:813-22. [PMID: 33862417 DOI: 10.1016/j.dsx.2021.03.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
13 Kim SW, Jeon JH, Moon JS, Kim MK. High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study. Endocrinol Metab (Seoul) 2021;36:800-9. [PMID: 34418914 DOI: 10.3803/EnM.2021.1040] [Reference Citation Analysis]
14 Campos-Murguía A, Román-Calleja BM, González-Regueiro JA, Hurtado-Díaz-de-León I, Solís-Ortega AA, Flores-García NC, García-Juárez I, Ruiz-Margáin A, Macías-Rodríguez RU. Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. World J Gastroenterol 2021; 27(33): 5502-5519 [PMID: 34588748 DOI: 10.3748/wjg.v27.i33.5502] [Reference Citation Analysis]
15 Yao R, Zhu L, Wang J, Liu J, Xue R, Xue L, Liu L, Li C, Zhao H, Cheng J, Huang S, Li Y, Zhao XA, Zhu C, Li M, Huang R, Wu C. Risk of severe illness of COVID-19 patients with NAFLD and increased NAFLD fibrosis scores. J Clin Lab Anal 2021;35:e23880. [PMID: 34213039 DOI: 10.1002/jcla.23880] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Middleton P, Hsu C, Lythgoe MP. Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies. BMJ Open Gastroenterol 2021;8:e000739. [PMID: 34675033 DOI: 10.1136/bmjgast-2021-000739] [Reference Citation Analysis]
17 Xu Y, Yang X, Bian H, Xia M. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management. Lipids Health Dis 2021;20:126. [PMID: 34602072 DOI: 10.1186/s12944-021-01564-z] [Reference Citation Analysis]
18 Liu M, Mei K, Tan Z, Huang S, Liu F, Deng C, Ma J, Yu P, Liu X, Marasco G. Liver Fibrosis Scores and Hospitalization, Mechanical Ventilation, Severity, and Death in Patients with COVID-19: A Systematic Review and Dose-Response Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-11. [DOI: 10.1155/2022/7235860] [Reference Citation Analysis]
19 Di Sessa A, Lanzaro F, Zarrilli S, Picone V, Guarino S, Miraglia del Giudice E, Marzuillo P. COVID-19 and pediatric fatty liver disease: Is there interplay? World J Gastroenterol 2021; 27(22): 3064-3072 [PMID: 34168408 DOI: 10.3748/wjg.v27.i22.3064] [Reference Citation Analysis]
20 Yan T, Xiao R, Wang N, Shang R, Lin G. Obesity and severe coronavirus disease 2019: molecular mechanisms, paths forward, and therapeutic opportunities. Theranostics 2021;11:8234-53. [PMID: 34373739 DOI: 10.7150/thno.59293] [Reference Citation Analysis]
21 Ekpanyapong S, Bunchorntavakul C, Reddy KR. COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later. J Viral Hepat 2021. [PMID: 34352133 DOI: 10.1111/jvh.13590] [Reference Citation Analysis]
22 Gracia-Ramos AE, Jaquez-Quintana JO, Contreras-Omaña R, Auron M. Liver dysfunction and SARS-CoV-2 infection. World J Gastroenterol 2021; 27(26): 3951-3970 [PMID: 34326607 DOI: 10.3748/wjg.v27.i26.3951] [Cited by in F6Publishing: 1] [Reference Citation Analysis]